BIA regional focus: cell & gene therapies at Stevenage


Tuesday 8 September 2020

Join us online on our virtual event platform for this networking event with a regional focus on cell and gene therapies at Stevenage.

This a great opportunity to network, meet new contacts, and hear from industry speakers discussing "How can we support scaling C&GT companies so that they remain in the UK".

Agenda

15.30:  Sign in and networking
16.00:  BIA update, Steve Bates, CEO, BIA
16:10:  Welcome and update from SBC, Sally Ann Forsyth, CEO, Stevenage Bioscience Catalyst
16:15:  Panel discussion - 
How can we support scaling C&GT companies so that they remain in the UK
               
Chaired by Oliver Hardick (Puridify/Cytiva)
                Adam Hacker (Autolus)
               John Lunger (Adaptimmune)
               Natalia Misciattelli (Freeline Therapeutics)
17:15:  Networking
18:15:  Close

Virtual format & tech requirements

We are excited to bring you this BIA regional focused networking event in virtual format.

You will be able to join us online to network and, similar to an in-person event, move from virtual table to table to mingle with other attendees. The platform we will be using also includes useful features which will allow you to message directly with other attendees and share LinkedIn details to connect. There is also a general chat for all attendees.

During the presentations/discussion you will be able to submit and vote on audience questions and we will try our best to cover everything in the time allocated.

What are the technical requirements to attend the virtual event?

  • There is no software installation or download required.
  • Please attend using a laptop or desktop computer with audio and video capabilities (webcam and microphone). The mobile or tablet views are still in the beta stage.
  • You will need to use one of the supported browsers to have the best user experience:
    Chrome, Safari, or Firefox.
  • If you want to check the technical requirements in more detail, you can view their checklist here.

If your company has firewalls or browsing restrictions in place, please test your connection and liaise with your IT team in advance to ensure you are able to fully participate in the event.

Cost and T&Cs

This event is free to attend for both members and non-members.

By registering for this event you accept our Terms & Conditions.

 

Speakers

Steve Bates

Chief Executive Officer

BIA

Steve Bates has been the CEO of the UK Bioindustry Association since 2012. He currently chairs the International Council of Biotech Associations and has been a Board member of Europabio since 2015. Steve is the visible face of the vibrant UK life sciences industry to government and media. He sits on the UK’s Life Sciences Council and Life Sciences Industrial Strategy Implementation Board. Steve has championed with government effective industrial incentives like the Biomedical Cataylst which have crowded-in private sector investment into UK SMES. He has forged links for the sector across the USA, Europe and in China. In his time at the BIA Steve has developed new member groups focused on cell and gene therapy, genomics and engineered biology. A strong advocate of partnership working, Steve champions sector collaboration with research charities and academia. Proud to lead an organisation with a diverse Board with over 40% female representation, Steve is committed to next generation talent and developing the skills needed for the sector to flourish. Before the BIA, Steve worked for Genzyme and as an advisor to the UK Government of Tony Blair. He was made OBE for services to innovation in 2017.

Dr Sally Ann Forsyth

Chief Executive Officer

Stevenage Bioscience Catalyst

Sally Ann has been responsible for the strategy, growth and development of 4 internationally recognised science parks including Harwell Oxford (STFC), Colworth Science Park (Unilever), Norwich Research Park (BBSRC) and most recently Stevenage Bioscience Catalyst (GSK/Wellcome). She began her career with Unilever as part of the management training scheme and later had lead responsibility for In-Licensing, Strategic Alliances and Open Innovation within the Unilever Foods and Discovery divisions. Being part of the founding team of Unilever Ventures and Unilever Technology Ventures gave Sally Ann an insight into the needs of growing companies. She gained her property experience through Goodman International where she was Director of Science Parks responsible for the development and management of their UK portfolio.

Sally Ann is passionate about the translation of UK science into world leading innovations and the creation of supportive environments to help early stage companies grow. She has a PhD in molecular biology from the University of Cambridge and is a qualified management accountant (CGMA).

Dr Oliver Hardick

Business Leader

Cytiva

Oliver’s academic expertise is in the field of novel purification approaches in bioprocessing having completed an Engineering doctorate at University College London in the department of Biochemical Engineering. In 2013 he founded Puridify, which was sold to GE Healthcare in 2017 to continue the development and commercialisation of novel bioprocessing platform technologies allowing for the cost effective manufacture of a wide range of existing and new biomolecule products including viral vectors.

As a Director of Puridify and Business Leader at Cytiva (formerly GE Healthcare) Oliver continues to support the innovation, strategic development and commercialisation of technology, interacting with biotherapeutic manufacturers globally through this process. He represents UCL as an honorary lecturer and regards industry-academia links as critical for the development of our industry. He is also an elected board member of BioIndustry Association (BIA), a trade association promoting the ecosystem for innovative life sciences in the UK.

Dr Adam Hacker

SVP, Regulatory Affairs

Autolus

Adam Hacker has over 20 years’ experience in the pharmaceutical industry. He joined Autolus in August 2018, as Senior Vice President, with global Regulatory and Quality responsibilities for Autolus’ CAT T portfolio and is both a member of the Executive Committee and Chair of the Development Committee.

Prior to joining Autolus, Adam spent ten years at Janssen Pharmaceuticals, where he most recently served as VP and Regulatory Head of Vaccines and Scientific Innovation Projects. During his tenure he also led haematology and oncology therapeutic areas for regulatory and medical affairs functions.

Adam earned a PhD in developmental molecular biology from the National Institute of Medical Research, London and holds an undergraduate Biology degree from Oxford University.

John Lunger

Chief Patient Supply Officer

Adaptimmune

John Lunger has served as Adaptimmune’s Chief Patient Supply Officer since August 2019 and leads the teams responsible for producing and delivering products to patients, accelerating supply execution, and optimizing the supply chain to be ready for commercialization. Prior to this, he was Senior Vice President, Manufacturing and Supply Chain at Adaptimmune, responsible for clinical manufacturing and global supply of Adaptimmune’s autologous T-cell therapy products, having joined the company in March 2017.

Previously, John was Head of Supply Chain and Commercial Product Supply at Merrimack Pharmaceuticals where he led clinical and commercial supply chain as well as the cross functional supply team for Merrimack’s first commercial product. Earlier in his career, he held various senior manufacturing, operational, and strategy roles with VWR International, Pfizer, and Wyeth Pharmaceuticals. In his nearly 10 years with Wyeth he held a number of leadership positions, including operations and supply chain strategy, supply management, procurement and strategic sourcing, business systems implementation, generic pharmaceutical business management, and site operations management in a pharmaceutical manufacturing plant in Ireland. John began his career serving as a nuclear trained officer on a US Navy submarine followed by strategic consulting with Accenture.

Natalia Misciattelli

Senior VP, Strategy and Business Operations

Freeline Therapeutics

Natalia offers broad strategic and operating model experience with top-tier multinational pharmaceutical companies.

Before joining Freeline, Natalia worked for over 20 years in the life sciences sector, most recently as a partner at PA Consulting running strategy and transformation programmes for life sciences clients globally. She has broad strategic experience, spanning corporate strategies, pipeline and product strategies, and compound and technology strategies for top-tier multinational pharmaceutical companies, including Pfizer, Novartis, and Johnson & Johnson.

She has designed and set up new operating models for organisations, often underpinned by new partnership models and sourcing. Previously, she was in Corporate Development & Strategy at General Electric (GE) Healthcare, starting her career at Arthur Andersen in London, UK.

She holds a BSc and a PhD in Marine Microbiology from Bangor University, University of Wales, UK.


Event partner

 

Thank you to our event supporter


 

BIA Annual Supporters